Seqens Seqens

X

Find the latest Drugs in Development and Pipeline Prospector News of Chiltern International Ltd.

  • Webinars & Exhibitions

PharmaCompass
Send me more info on How To Grow My Bussiness Digitally?
Chiltern International Ltd
unitedkingdom_new Flag
Country
Country
United Kingdom
Address
Address
171 Bath Road Slough, Berkshire
Telephone
Telephone
+44 0 1753 512 000

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Details:

In preclinical models, MCLA-158 binding triggers EGFR degradation in LGR5+ CSCs and is designed to have two different mechanisms of action. The first entails blocking of growth and survival pathways in cancer initiating cells.


Lead Product(s): Petosemtamab

Therapeutic Area: Oncology Product Name: MCLA-158

Highest Development Status: Phase IProduct Type: Large molecule

Recipient: Merus

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable October 07, 2021

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty
Post Enquiry
POST ENQUIRY